Janux Therapeutics (NASDAQ:JANX) Raised to "Hold" at Wall Street Zen
Wall Street Zen has upgraded Janux Therapeutics (NASDAQ:JANX) from a "sell" to a "hold" rating, though the consensus among analysts remains a "Moderate Buy" with an average target price of $56.91. The company recently reported better-than-expected earnings per share and revenue for the quarter. Despite some target cuts and mixed ratings from other firms, Janux Therapeutics trades with a market capitalization of approximately $902.7 million and high institutional ownership.
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
Janux Therapeutics announced it received a $35 million milestone payment from Bristol Myers Squibb after nominating a development candidate for a tumor-activated therapy under their collaboration. This milestone highlights progress in translating Janux’s TRACTr platform into potential cancer treatments. The therapy is being developed for an undisclosed antigen found across multiple solid tumors, with Bristol Myers Squibb handling later-stage development and commercialization.
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
Janux Therapeutics has received a $35 million milestone payment from Bristol Myers Squibb after nominating a development candidate under their global collaboration. This candidate is a tumor-activated therapy targeting an undisclosed antigen for solid tumors, developed using Janux's TRACTr platform. The payment underscores progress in transforming Janux's platform technologies into potential cancer treatments and provides capital for its other pipeline programs.
71,016 shares tied to option exercise at JANX (NASDAQ: JANX) disclosed
A Form 144 filing by Janux Therapeutics (NASDAQ: JANX) disclosed proposed sales of common stock. The filing indicates 71,016 shares are tied to an option exercise dated April 2, 2026, and an additional 3,786 shares are from restricted stock vesting on January 1, 2026. The document also reports a past sale of 2,714 shares on January 2, 2026, which generated $37,263.22.
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
Janux Therapeutics announced it secured a $35 million milestone payment from Bristol Myers Squibb (BMY) after nominating a development candidate under their global collaboration. This candidate uses Janux's TRACTr platform for a tumor-activated therapy targeting an undisclosed antigen in solid tumors. The payment is part of a larger deal where Janux leads preclinical development and BMY handles clinical development and commercialization, with Janux also eligible for future milestone payments and royalties.
Bristol Myers Squibb Cancer Pact And Equity Push Raise Valuation Questions
Bristol Myers Squibb has reached a significant milestone by receiving a $35 million payment after Janux Therapeutics nominated a tumor-activated cancer therapeutic in their partnership. Concurrently, the company is expanding its "Standing in the Gaap" program to address equity gaps in multiple myeloma treatment. These developments, which include progress in R&D and social impact initiatives, provide investors with a comprehensive view of how Bristol Myers Squibb is shaping its pipeline and broader role in cancer care.
Janux Therapeutics Expects $35 Million Milestone Payment From Bristol-Myers Squibb
Janux Therapeutics announced it anticipates receiving a $35 million milestone payment from Bristol Myers Squibb related to their 2020 exclusive license agreement. This payment is triggered by Bristol Myers Squibb's decision to continue developing a JANAX compound following clinical data review. The clinical data supports further development of the compound, which targets a tumor-associated antigen.
Janux Therapeutics, Inc. announced that, under its collaboration with Bristol Myers Squibb, it has officially nominated a development candidate drug.
Janux Therapeutics, Inc. has nominated a development candidate drug under its collaboration with Bristol Myers Squibb, triggering a $35 million milestone payment. This nomination is a significant advancement in their tumor immunotherapy partnership and will support Janux Therapeutics' innovative therapy pipeline.
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
Janux Therapeutics has nominated a development candidate under its collaboration with Bristol Myers Squibb, triggering a $35 million milestone payment. This candidate, developed using Janux's TRACTr platform, targets an undisclosed solid tumor antigen. The milestone highlights Janux's strategy of internal innovation and strategic partnerships, with Bristol Myers Squibb responsible for clinical development and commercialization after IND submission.
Janux Therapeutics, Inc. announced that, under its collaboration with Bristol Myers Squibb, it has officially nominated a development candidate drug.
Janux Therapeutics, Inc. has officially nominated a development candidate drug under its collaboration with Bristol Myers Squibb, triggering a $35 million milestone payment. This nomination represents a significant advancement in tumor immunotherapy research and development for both companies. The payment will further support Janux Therapeutics' innovative therapy pipeline.
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57
The article states that Janux Therapeutics (JANX) has seen its price target decreased by 11.93%, bringing it down to $54.57. No further details about the reasons for this change or the analyst responsible are provided in the snippet.
Understanding the Setup: (JANX) and Scalable Risk
An analysis of Janux Therapeutics Inc. (NASDAQ: JANX) indicates near-term weak sentiment that may lead to a resumption of long-term weakness. The article highlights an exceptional 106.7:1 risk-reward short setup with a substantial downside target. AI-generated trading strategies are provided for different risk profiles, including position trading, momentum breakout, and risk hedging strategies.
Janux reports positive phase 1 results for JANX007 in mCRPC; stock down
Janux Therapeutics announced positive topline results from the Phase 1a portion of its Phase 1 clinical trial for JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). Despite the positive efficacy and safety observations, the company's stock experienced a significant drop, indicating market disappointment or profit-taking. The initial clinical data suggests promise for JANX007 as a potential treatment for this advanced form of prostate cancer.
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Janux Therapeutics (NASDAQ:JANX) holds a substantial cash reserve of US$342m, giving it a cash runway of over three years based on its current burn rate. While the company has yet to generate significant revenue or profits, its strong cash position suggests it has ample time to develop its oncology pipeline. Investors will be keenly watching how Janux allocates its capital to advance its therapeutic candidates.
Janux Therapeutics (NASDAQ:JANX) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen has downgraded Janux Therapeutics (NASDAQ:JANX) from "hold" to "sell." Despite this, the consensus among 14 analysts remains a "Moderate Buy" with an average price target of $56.91. The company recently surpassed quarterly EPS and revenue estimates, but insiders have sold approximately 19,033 shares in the last 90 days.
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57
This article reports that the price target for Janux Therapeutics (JANX) has been reduced by 11.93%, bringing it down to $54.57.
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Janux Therapeutics (NASDAQ:JANX) has received a "Moderate Buy" consensus rating from fourteen analysts, with an average 12-month price target of $56.91, significantly higher than its recent open price of $14.06. The company recently surpassed quarterly earnings estimates, reporting ($0.51) EPS against an estimated ($0.65) and revenue of $7.88 million compared to $0.08 million expected. Despite recent insider selling, institutional investors hold a substantial 75% ownership stake in Janux Therapeutics.
JANX SEC Filings - Janux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Janux Therapeutics, Inc. (JANX) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material event forms, and insider trading information. It details recent filings such as FMR LLC's 5.8% stake, insider trades by a Chief Business Officer, Q3 2025 financial results showing a Merck milestone, and executive changes. The platform also offers AI-powered summaries and tools for investors to analyze the company's financial and corporate developments.
Advanced Renal Cell Carcinoma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeuti
A DelveInsight report indicates that over 50 companies are actively developing more than 60 Advanced Renal Cell Carcinoma (RCC) treatment therapies, covering various stages from pre-clinical to marketed phases. The pipeline includes therapies from companies like Molecure S.A., Daiichi Sankyo, and Merck Sharp & Dohme, with several drugs, such as OATD-02 and Belzutifan, showing promising clinical trial results. The Advanced RCC market is driven by increasing prevalence and R&D activities, though high treatment costs and side effects remain challenges.
The Technical Signals Behind (JANX) That Institutions Follow
This article analyzes Janux Therapeutics Inc. (NASDAQ: JANX) using AI models to identify technical signals and institutional trading strategies. It highlights a potential shift from positive near-term sentiment, details specific entry/exit points for long, breakout, and short positions, and provides multi-timeframe signal analysis for support and resistance levels.
Precision Trading with Janux Therapeutics Inc. (JANX) Risk Zones
This article analyzes Janux Therapeutics Inc. (JANX) using AI models to provide trading strategies. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying a mid-channel oscillation pattern. The analysis offers three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, emphasizing risk management and potential entry/exit points for traders.
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring The 316.79% Potential Upside
Janux Therapeutics (NASDAQ: JANX) is highlighted as an intriguing opportunity in biopharma, with analysts projecting a 316.79% potential upside, driven by its innovative cancer treatment platforms. Despite being a pre-revenue company facing financial losses and typical biotech investment risks, its promising clinical pipeline, including JANX007 and JANX008, and a strategic collaboration with Merck, underscore its high-risk, high-reward profile. The article details its current market standing, technical indicators, and analyst support, positioning it as a stock to watch for investors seeking significant growth.
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial
Janux Therapeutics Inc. (JANX) has commenced patient dosing in a Phase 1 study of JANX011 for autoimmune diseases. This drug, designed on the company’s ARM platform, aims for deep and durable immune reset by depleting CD19-expressing B cells. The company highlights this as a significant milestone, with potential broader implications beyond autoimmune diseases, including hematologic malignancies.
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial
Janux Therapeutics, Inc. (JANX) has initiated patient dosing for JANX011 in a Phase 1 study targeting autoimmune diseases. This drug, designed using the company's ARM platform, aims for deep and durable immune reset by depleting CD19-expressing B cells. This milestone marks the first clinical evaluation of Janux's ARM platform, with potential broader applications beyond autoimmune diseases, including hematologic malignancies.
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Analysts
Janux Therapeutics (NASDAQ:JANX) has received a consensus "Moderate Buy" rating from 15 analysts, with an average 12-month target price of $60.08, despite recent price target cuts from several firms. Insiders, including CEO David Alan Campbell, have sold shares totaling over $371,000 in the past three months. The clinical-stage immuno-oncology biotech has a market capitalization of approximately $824 million and a negative P/E ratio.
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives
Janux Therapeutics reported a net loss of US$113.6 million for FY 2025, with quarterly revenue fluctuating between US$0 and US$10 million. Despite a forecast of 63.7% revenue growth, the company is not expected to reach profitability in the next three years, and earnings are projected to decline by 9% annually. This financial performance, coupled with a volatile share price and a low P/B ratio of 0.8x, raises concerns for cautious investors given the persistent losses and lack of a clear path to profitability.
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives
Janux Therapeutics (JANX) reported a Q4 FY 2025 basic EPS loss of US$0.51 and a net loss of US$113.6 million for the trailing 12 months, indicating deepening losses. Despite a forecast of 63.7% annual revenue growth, the company is not expected to achieve profitability within the next three years, with earnings predicted to decline by 9% annually. The stock trades at a low P/B of 0.8x, reflecting investor concerns over persistent losses and earnings decline, coupled with high share price volatility.
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS
Janux Therapeutics (NASDAQ:JANX) reported quarterly earnings of ($0.51) EPS, surpassing analyst estimates by $0.14. Despite insider selling, institutional ownership is high, and analysts generally maintain a "Moderate Buy" rating with an average target price of $60.08, though some firms have lowered price objectives. The company's stock traded up 0.7% to $13.80 on the news.
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Janux Therapeutics announced its fourth quarter and full-year 2025 financial results, highlighting significant clinical and strategic advancements. The company reported continued progress in its TRACTr programs, with JANX007 showing durable clinical activity in metastatic castration-resistant prostate cancer and JANX008 advancing in expansion cohorts. Janux also initiated a Phase 1 study for JANX011 and entered a strategic collaboration with Bristol Myers Squibb, bolstering its financial position with $966.6 million in cash and short-term investments.
Key facts: Janux Therapeutics Receives Strong Buy Ratings; Partners with BMS
Janux Therapeutics (JANX) has received overwhelmingly positive analyst ratings, with 18 'strong buy' or 'buy' recommendations and no 'sell' ratings. Analysts predict a significant 74.4% upside with a median 12-month price target of $53.50. The company has also announced a partnership with Bristol Myers Squibb to develop a new tumor-activated therapy, potentially involving $800 million in milestone payments.
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price
Cantor Fitzgerald has reduced its price target for Janux Therapeutics (NASDAQ:JANX) from $150 to $100, though it maintains an "overweight" rating. Other analysts have also lowered their targets, resulting in a consensus "Moderate Buy" rating and an average price target of $55.58, significantly higher than Janux's current trading price of around $13.50. The company recently reported better-than-expected Q4 earnings and revenue, but insiders have been net sellers, while institutional investors hold a large portion of the stock.
Bristol Myers deal and wider 2025 loss at Janux Therapeutics (JANX)
Janux Therapeutics reported a widened net loss of $157.7 million in 2025 due to increased R&D spending on its clinical pipeline. The company also announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb, which includes $50 million in upfront and near-term milestone payments and potential additional milestones up to $800 million, validating Janux’s platform and providing substantial funding. Despite the increased losses, Janux ended 2025 with $966.6 million in cash, cash equivalents, and short-term investments, supporting its continued advancement of TRACTr™ and ARM clinical programs.
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX)
Analysts from TD Cowen, Marc Frahm and Phil Nadeau, have maintained bullish ratings on Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX) respectively. Both companies received "Strong Buy" consensus ratings with significant upside potential from their current stock prices. The analysts' positive sentiments are based on their assessments within the Healthcare sector.
Janux Therapeutics Inc (JANX) Receives a Buy from Wedbush
Wedbush has maintained a Buy rating on Janux Therapeutics Inc (JANX) with a price target of $45.00, while the analyst consensus is a Strong Buy with an average price target of $52.00. The company reported $10 million in quarterly revenue and a GAAP net loss of $24.31 million for the quarter ending September 30, showing an increase in revenue compared to the previous year. Despite positive analyst sentiment, corporate insider sentiment on the stock is negative due to increased selling activity among insiders.
JANX Financials: Income Statement, Balance Sheet & Cash Flow
This article presents the financial statements for Janux Therapeutics, Inc. (JANX), including its income statement, balance sheet, and cash flow statement, covering six years of annual and quarterly data through FY2025. It details key financial metrics, profitability, growth, leverage, liquidity, and cash flow, revealing a company with declining revenue, negative operating margins, and low earnings quality despite strong liquidity and low debt. The analysis also includes a Piotroski F-Score and an estimated cash runway.
Where is Janux Therapeutics (JANX) Headed According to Analysts?
Janux Therapeutics (JANX) is highlighted as a top immunotherapy stock, with JonesTrading maintaining a Buy rating and a $50 price target. The company recently announced a collaboration with Bristol Myers Squibb to develop a novel tumor-activated therapeutic, validating Janux's platform and expanding its oncology reach. Janux will handle preclinical development, while Bristol Myers Squibb will manage subsequent development and commercialization globally.
Janux therapeutics doses first participant in JANX011 phase 1 trial
Janux Therapeutics has dosed the first participant in a Phase 1 clinical study for JANX011, a CD19-targeted bispecific therapy for autoimmune diseases. This marks the first clinical evaluation of their Adaptive Immune Response Modulator (ARM) platform, aiming to deplete CD19-expressing B cells without lymphodepletion. The company is also collaborating with Bristol Myers Squibb and recently appointed a new Chief Medical Officer, though its stock was downgraded by Clear Street due to concerns about its cancer treatment platform.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics reported that the first patient has been dosed in a Phase 1 clinical study for JANX011, a CD19-targeted bispecific engineered using its Adaptive Immune Response Modulator (ARM) platform. JANX011 is designed for autoimmune diseases to achieve deep and durable immune reset via targeted depletion of CD19-expressing B cells. This milestone marks the first clinical evaluation of Janux's ARM platform, which aims to provide sustained B-cell depletion with improved safety compared to conventional T-cell engagers.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics has announced that the first patient has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using its proprietary Adaptive Immune Response Modulator (ARM) platform. JANX011 is being developed for autoimmune diseases and aims to achieve deep and durable immune reset through targeted depletion of CD19-expressing B cells. This milestone represents the first clinical evaluation of Janux's ARM platform, which is designed to enable sustained target B-cell depletion with improved safety and convenience compared to conventional T-cell engagers.
Janux therapeutics doses first participant in JANX011 phase 1 trial
Janux Therapeutics has dosed the first participant in its Phase 1 clinical study for JANX011, a CD19-targeted bispecific therapy for autoimmune diseases, marking a key milestone for its ARM platform. The therapy aims to deplete B cells and reset the immune system, with preclinical studies showing promising results without requiring harsh pre-conditioning. This development follows recent news of a collaboration with Bristol Myers Squibb and a downgrade from Clear Street due to concerns about Janux's cancer treatment platform.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics has dosed the first patient in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific developed for autoimmune diseases using its Adaptive Immune Response Modulator (ARM) platform. JANX011 aims for deep and durable immune reset through targeted B-cell depletion and is the first clinical candidate from the ARM platform. Preclinical studies showed promising results with strong B-cell depletion and low cytokine levels, suggesting a broad safety window and potential for CAR-T like effects in autoimmune patients.
Janux Therapeutics Announces First Patient Dosed In Phase 1 Study Of Janx011
Janux Therapeutics has announced that the first patient has been dosed in its Phase 1 study of Janx011. This development marks a significant step forward for the company's clinical trials. The news was reported by Refinitiv via TradingView.
Janux Therapeutics : JANX
Janux Therapeutics Inc. (JANX) is a biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment using its proprietary TRACTr and TRACIr technologies. The company is working on treatments that activate T cells to combat tumors, targeting various cancer markers. Analysts are bullish on JANX, with aggressive price targets implying significant gains for the stock.
Trading the Move, Not the Narrative: (JANX) Edition
This article analyzes Janux Therapeutics Inc. (NASDAQ: JANX), highlighting strong near-term sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 122.5:1 risk-reward setup targeting a 40.0% gain. The piece also details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles.
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
Janux Therapeutics (JANX) has seen its stock gain 1.8% in the past four weeks, with Wall Street analysts projecting a potential upside of 319.2% based on a mean price target of $58.65. This optimism is further supported by strong agreement among analysts on the company's earnings prospects, evidenced by upward revisions in EPS estimates, and a Zacks Rank #2 (Buy) rating. Despite the typical skepticism advised for price targets, the trend in earnings estimate revisions suggests a legitimate reason for potential stock upside.
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007
Janux Therapeutics (JANX) is facing platform risk due to a lack of durability data for its drug candidate JANX007 and the absence of new data for JANX008, leading to a downgrade by Clear Street. Despite these concerns, Janux recently entered an exclusive worldwide license and collaboration agreement with Bristol Myers (BMY) for a novel tumor-activated therapy, with potential milestones totaling over $800 million. The company is developing immunotherapies to treat cancer but is currently recommended with caution given rising competitive pressures and execution risks.
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007
This article focuses on Janux Therapeutics (JANX) and the potential platform risk associated with its drug candidate JANX007, particularly due to a lack of durability data. The primary concern is whether the drug's effects last long enough, which could impact its overall efficacy and market potential. Further clinical data will be crucial in addressing these concerns for investors and the medical community.
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages
Janux Therapeutics (NASDAQ: JANX) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 12-month target price of $60.08. Despite this, company insiders, including CEO David Campbell, have recently sold 25,699 shares valued at approximately $471K. The company's stock currently trades around $13.71, with a market capitalization of about $825 million, and recently reported an EPS of ($0.39) and revenue of $10.0 million, both exceeding estimates.
Janux Therapeutics Repeat Insider Selling Not A Positive Indicator
Several insiders at Janux Therapeutics, including President David Campbell, have sold shares over the past year, with no insider purchases recorded. The largest sale involved US$111k worth of shares at US$13.73, slightly below the current price. While insiders still own 6.6% of the company, this consistent selling activity may be a red flag for shareholders.
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
Bristol Myers Squibb (BMY) is strategically expanding its oncology pipeline through collaborations with Janux Therapeutics, Microsoft, and BioNTech to develop novel cancer therapies and improve early detection. These partnerships aim to boost BMY's portfolio as its legacy drugs face generic competition, positioning it to compete with pharmaceutical giants like Merck and Pfizer in the growing oncology market. Despite valuation at a discount to the large-cap pharma industry, BMY's stock has seen significant gains, though its 2025 EPS estimates have declined slightly.
